Celea Therapeutics has announced the appointment of Paul Audhya, MD, MBA, as their new Chief Medical Officer. This decision reflects the company's commitment to strengthening its leadership in the biopharmaceutical sector.
Who to call at Celea Therapeutics, and when
A new leader at Celea Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Celea Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Celea Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Celea Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Celea Therapeutics
Location
Boston, Massachusetts, United States
About
Celea Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with serious respiratory diseases. The company is focused on developing deupirfenidone (LYT-100) as a potential new standard of care for idiopathic pulmonary fibrosis (IPF). Celea aims to deliver meaningful improvements for patients suffering from this disease with limited treatment options. The company is backed by a syndicate of top-tier healthcare investors.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Celea Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonBiotechnologyHealth CareTherapeuticsBiopharma